2019 | | Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study | 정성현 |
2022 | | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) | 안미선 |
2016 | | Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008) | 정성현 |
2015 | | Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). | 안미선 |
2012 | | Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study | 김효철 |
2017 | | Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia | 박준성 |
2007 | | Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. | - |
2013 | | Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. | 강석윤 |
2012 | | Phospholipase C activator m-3M3FBS protects against morbidity and mortality associated with sepsis | 박준성 |
2017 | | Phospholipase Cgamma1 suppresses foreign body giant cell formation by maintaining RUNX1 expression in macrophages | 박준성 |
1997 | | Plasma tissue factor antigen levels in capillary whole blood and venous blood: effect of tissue factor on prothrombin time. | 김효철 |
1999 | | Plasmafiltration and Synchronized cyclophosphamide therapy in SLE with aplastic anemia | 김효철, 남동기, 박해심 |
2022 | | POEMS Syndrome: Presented as Idiopathic Multicentric Castleman Disease of Plasma Cell Variant for Eight Years and Dramatic Treatment with Siltuximab Followed by Autologous Peripheral Blood Stem Cell Transplantation | 최윤석 |
2007 | | Polymerase Chain Reaction and Sequencing of Immunoglobulin Heavy Chain Gene Rearrangement in Formalin Fixed, Paraffin-embedded Tissue of Patients with B Cell Lymphoma | 김효철, 박일중, 박준성, 박준은, 이위교, 조성란, 한재호 |
2018 | | Post-Translational Regulation of the RSF1 Chromatin Remodeler under DNA Damage | 조혜성, 지재훈, 최용원 |
2024 | | Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma | 고영화, 이현우, 한재호, 함석진 |
2013 | | Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. | 박준성, 정성현 |
2012 | | Primary thyroid marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: clinical manifestation and outcome of a rare disease - consortium for improving survival of lymphoma study | 정성현 |
2021 | | PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer | 최진혁 |
2012 | | Profiling of differentially expressed genes in haemophilia A with inhibitor | 김효철, 이현우 |
2022 | | Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma | 고영화, 이현우, 한재호, 함석진 |
2021 | | Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13) | 강석윤 |
2012 | | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) | 정성현 |
2017 | | Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy | 고영화, 이현우 |
2018 | | Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in gastric cancer patients who underwent palliative chemotherapy | 강석윤, 안미선, 이현우, 최용원, 최진혁 |
1998 | | Prognostic Significance of the Number of Metastatic Lymph Nodes after Curative Resection in Patients with Gastric Cancer | 김효철, 남동기, 임호영, 최진혁 |
2017 | | Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis | 강석윤, 안영실, 윤준기, 이수진, 임현이 |
2016 | | Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study | 강석윤 |
2020 | | Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma | 이현우 |
2016 | | Prognostic value of negative interim 2-[(1)(8)F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma | 강대용, 안영실, 윤준기, 이수진, 이현우, 정성현 |
2016 | | Promotion of formyl peptide receptor 1-mediated neutrophil chemotactic migration by antimicrobial peptides isolated from the centipede Scolopendra subspinipes mutilans | 박준성 |
2008 | | Prospective Evaluation of Ultrathin Transnasal Esophagogastroduodenoscopy: Its Feasibility, Safety and Tolerance | 김진홍, 신성재, 유병무, 이광재, 이기명, 정성현, 정재연, 황재철 |
1997 | | Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. | 임호영 |
2018 | | Pseudo-Chediak-Higashi granules in myeloid cells in therapy-related AML with RUNX1-RUNX1T1 | 박준성, 조성란 |
2015 | | Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). | 강석윤 |
2020 | | Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2 | 노진, 박준성, 정성현, 한재호 |
2016 | | Radiation Therapy-First Strategy After Surgery With or Without Adjuvant Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer | 노오규, 박래웅, 박성용, 안미선, 오영택, 윤덕용, 이현우, 전미선, 최진혁, 허재성 |
2016 | | Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer | 노오규, 오영택, 이현우, 전미선, 조오연 |
2023 | | Radioimmunotherapy with 131I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma | 정성현 |
2015 | | Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21. | 이현우 |
2020 | | Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting | 이현우 |
2019 | | Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naive Korean Patients with Extensive-Disease Small Cell Lung Cancer | 최진혁 |
2023 | | Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation | 박준성 |
2024 | | Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study | 이현우 |
2020 | | Recent advances in the management of primary central nervous system lymphoma | 최윤석 |
1997 | | Relationship between p53 overexpression and gastric cancer progression. | 최진혁 |
2013 | | Retrovirus-mediated transduction of a cytosine deaminase gene preserves the stemness of mesenchymal stem cells. | 김성수, 김세혁, 박준성, 서해영, 이영돈, 장다영 |
2012 | | Risk Reducing Surgery in Carriers with Double Heterozygosity for BRCA1 and BRCA2 Mutations | 강두경, 강석윤, 김구상, 김태희, 박명철, 임현이, 장석준, 전미선, 정용식, 홍우성 |
2013 | | Role of CXCR2 on the immune modulating activity of α-iso-cubebenol a natural compound isolated from the Schisandra chinensis fruit. | 박준성 |
2019 | | S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial | 강석윤 |